263 related articles for article (PubMed ID: 35527239)
1. Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.
Katsumata M; Fujisawa T; Kamiya Y; Tanaka Y; Kamiya C; Inoue Y; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Maekawa M; Setou M; Watanabe H; Ikegami K; Suda T
BMC Pulm Med; 2022 May; 22(1):186. PubMed ID: 35527239
[TBL] [Abstract][Full Text] [Related]
2. Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium.
Kamiya Y; Fujisawa T; Katsumata M; Yasui H; Suzuki Y; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Setou M; Ito M; Suzuki T; Ikegami K; Suda T
Respir Res; 2020 Oct; 21(1):282. PubMed ID: 33109186
[TBL] [Abstract][Full Text] [Related]
3. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
Chapman KR; Beeh KM; Beier J; Bateman ED; D'Urzo A; Nutbrown R; Henley M; Chen H; Overend T; D'Andrea P
BMC Pulm Med; 2014 Jan; 14():4. PubMed ID: 24438744
[TBL] [Abstract][Full Text] [Related]
4. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS
Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
[TBL] [Abstract][Full Text] [Related]
5. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R; Banerji D
Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
[TBL] [Abstract][Full Text] [Related]
6. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
D'Urzo A; Bader G; Shen S; Goyal P; Altman P
NPJ Prim Care Respir Med; 2018 May; 28(1):18. PubMed ID: 29795478
[TBL] [Abstract][Full Text] [Related]
7. Muscarinic Receptor Antagonists.
Matera MG; Cazzola M
Handb Exp Pharmacol; 2017; 237():41-62. PubMed ID: 27787709
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
9. Understanding the role of long-acting muscarinic antagonists in asthma treatment.
Muiser S; Gosens R; van den Berge M; Kerstjens HAM
Ann Allergy Asthma Immunol; 2022 Apr; 128(4):352-360. PubMed ID: 35074516
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
Ismaila AS; Huisman EL; Punekar YS; Karabis A
Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
[TBL] [Abstract][Full Text] [Related]
11. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
12. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics.
Blais CM; Davis BE; Cockcroft DW
Respir Med; 2016 Sep; 118():96-101. PubMed ID: 27578477
[TBL] [Abstract][Full Text] [Related]
13. Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.
Jones PW
Ther Adv Respir Dis; 2015 Jun; 9(3):84-96. PubMed ID: 25801643
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
15. Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review.
Rogliani P; Ritondo BL; Puxeddu E; Cazzola M; Calzetta L
Respir Med; 2021; 189():106639. PubMed ID: 34628125
[TBL] [Abstract][Full Text] [Related]
16. Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.
Trifilieff A; Ethell BT; Sykes DA; Watson KJ; Collingwood S; Charlton SJ; Kent TC
Toxicol Appl Pharmacol; 2015 Aug; 287(1):9-16. PubMed ID: 26026369
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.
Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T
Respir Investig; 2020 May; 58(3):155-168. PubMed ID: 32094077
[TBL] [Abstract][Full Text] [Related]
19. Current long-acting muscarinic antagonists for the treatment of asthma.
Ora J; Calzetta L; Ritondo BL; Matera MG; Rogliani P
Expert Opin Pharmacother; 2021 Dec; 22(17):2343-2357. PubMed ID: 34219573
[TBL] [Abstract][Full Text] [Related]
20. An autocrine ATP release mechanism regulates basal ciliary activity in airway epithelium.
Droguett K; Rios M; Carreño DV; Navarrete C; Fuentes C; Villalón M; Barrera NP
J Physiol; 2017 Jul; 595(14):4755-4767. PubMed ID: 28422293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
